Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
ncarol.com/10292365

MIYUN, China - ncarol.com -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on ncarol.com

• CCHR Rejects Global Psychiatric Push to Electroshock Children
• iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
• Americans Leave Behind or Discard 42% of Their Belongings When Moving Out for the First Time, Talker Research Finds
• Central Florida Luxury Real Estate Firm DANHOLM COLLECTION Partners with Luxury Presence to Expand Global Buyer Reach
• Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com